BR0010757A - Inibidores de peptìdeo de fusão de longa duração de infecção viral - Google Patents

Inibidores de peptìdeo de fusão de longa duração de infecção viral

Info

Publication number
BR0010757A
BR0010757A BR0010757-3A BR0010757A BR0010757A BR 0010757 A BR0010757 A BR 0010757A BR 0010757 A BR0010757 A BR 0010757A BR 0010757 A BR0010757 A BR 0010757A
Authority
BR
Brazil
Prior art keywords
long
viral infection
fusion peptide
peptide inhibitors
peptides
Prior art date
Application number
BR0010757-3A
Other languages
English (en)
Inventor
Dominique P Bridon
Robert S Dufresne
Nissab Boudjellab
Martin Robitaille
Peter G Milner
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010757(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Publication of BR0010757A publication Critical patent/BR0010757A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "INIBIDORES DE PEPTìDEO DE FUSãO DE LONGA DURAçãO DE INFECçãO VIRAL". Peptídeos exibindo atividade antiviral e antifusogênica são modificados para fornecer maior estabilidade e meia-vida in vivo melhorada. Os peptídeos selecionados incluem inibidores de fusão DP 178 e DP 107 e peptídeos relacionados e análogos destes. Os peptídeos modificados são capazes de formar ligações covalentes com um ou mais componentes do sangue, preferivelmente um componente móvel do sangue.
BR0010757-3A 1999-05-17 2000-05-17 Inibidores de peptìdeo de fusão de longa duração de infecção viral BR0010757A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
PCT/US2000/013651 WO2000069902A1 (en) 1999-05-17 2000-05-17 Long lasting fusion peptide inhibitors or viral infection

Publications (1)

Publication Number Publication Date
BR0010757A true BR0010757A (pt) 2002-02-19

Family

ID=26832297

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010757-3A BR0010757A (pt) 1999-05-17 2000-05-17 Inibidores de peptìdeo de fusão de longa duração de infecção viral

Country Status (14)

Country Link
US (4) US7582301B1 (pt)
EP (3) EP1264840B1 (pt)
JP (3) JP4216480B2 (pt)
CN (1) CN1351611A (pt)
AT (2) ATE443714T1 (pt)
AU (1) AU761591B2 (pt)
BR (1) BR0010757A (pt)
CA (1) CA2372338A1 (pt)
DE (2) DE60043021D1 (pt)
DK (1) DK1264840T3 (pt)
ES (2) ES2334106T3 (pt)
HK (1) HK1053128A1 (pt)
PT (1) PT1264840E (pt)
WO (1) WO2000069902A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE60043021D1 (de) 1999-05-17 2009-11-05 Conjuchem Biotechnologies Inc Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
JP4267444B2 (ja) 2001-06-15 2009-05-27 エフ．ホフマン−ラ ロシュ アーゲー Ｇｐ４１フラグメントのアセチル化
CA2500248C (en) 2002-09-24 2013-03-19 Frontier Biotechnologies Co., Ltd. Peptide derivative fusion inhibitors of hiv infection
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
RS20060578A (en) * 2004-04-23 2008-11-28 Conjuchem Biotechnologies Inc., Method for the purification of albumin conjugates
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种***的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
DK1989220T3 (da) 2006-02-02 2012-04-02 Trimeris Inc HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AU2007286451A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
EP2594583A1 (en) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
EP2453903B1 (en) * 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes
KR101874834B1 (ko) 2009-10-30 2018-07-05 알부메딕스 에이/에스 알부민 변이체
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
JP5757639B2 (ja) 2010-09-14 2015-07-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セルピンフィンガー融合ポリペプチド
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
JP6430828B2 (ja) 2011-05-05 2018-11-28 アルブミディクス リミティド アルブミン変異体
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
EP2834264A1 (en) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
US20160030518A1 (en) * 2013-04-03 2016-02-04 The Regents Of The University Of California Compositions and methods for inhibiting viral activity
CN105992770B (zh) 2013-11-01 2021-06-25 奥斯陆大学 白蛋白的变体及其用途
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
CA3004790A1 (en) 2015-11-10 2017-05-18 Visterra, Inc. Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN116710146A (zh) 2020-04-03 2023-09-05 威特拉公司 抗体分子-药物偶联物及其用途
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
NZ254640A (en) 1992-07-20 1997-04-24 Univ Duke Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
EP1007561B1 (en) * 1997-11-07 2002-04-17 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
CA2291066A1 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AU773428B2 (en) * 1998-10-13 2004-05-27 Peptide Biosciences, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
DE60043021D1 (de) 1999-05-17 2009-11-05 Conjuchem Biotechnologies Inc Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
RS20060578A (en) * 2004-04-23 2008-11-28 Conjuchem Biotechnologies Inc., Method for the purification of albumin conjugates
CA2565658A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Also Published As

Publication number Publication date
AU761591B2 (en) 2003-06-05
EP1264840B1 (en) 2009-09-23
US20080199483A1 (en) 2008-08-21
ES2334106T3 (es) 2010-03-05
EP2110381A1 (en) 2009-10-21
ATE443714T1 (de) 2009-10-15
EP1179012B2 (en) 2009-07-15
US20050070475A1 (en) 2005-03-31
CN1351611A (zh) 2002-05-29
DE60000665T2 (de) 2003-06-26
JP2008101021A (ja) 2008-05-01
ES2185595T5 (es) 2009-12-17
EP1179012A1 (en) 2002-02-13
US20080176794A1 (en) 2008-07-24
EP1264840A1 (en) 2002-12-11
EP1179012B9 (en) 2003-09-10
EP1179012B1 (en) 2002-10-23
CA2372338A1 (en) 2000-11-23
ATE226593T1 (de) 2002-11-15
AU5027100A (en) 2000-12-05
DK1264840T3 (da) 2009-11-16
HK1053128A1 (en) 2003-10-10
US7582301B1 (en) 2009-09-01
DE60000665T3 (de) 2009-10-29
JP4216480B2 (ja) 2009-01-28
JP2002544287A (ja) 2002-12-24
WO2000069902A1 (en) 2000-11-23
PT1264840E (pt) 2010-01-04
ES2185595T3 (es) 2003-05-01
JP2009167208A (ja) 2009-07-30
DE60043021D1 (de) 2009-11-05
US7608271B2 (en) 2009-10-27
DE60000665D1 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
BR0010757A (pt) Inibidores de peptìdeo de fusão de longa duração de infecção viral
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
LU92175I2 (fr) Lixisénatide
FI933740A (fi) PEG-interferonkonjugat
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
BR9813284B1 (pt) aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
ATE516820T1 (de) Pegyliertes interleukin 10
EP1185545A4 (en) CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINE AND THERAPEUTICA
ES2156731A1 (es) Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
DK0739201T3 (da) Mikrogranuler af 5-nitro-imidazolderivater
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
ATE427736T1 (de) Pharmazeutische zubereitungen zur parenteralen verabreichung enthaltend epothilon
RU93050376A (ru) Полиэтилен гликолевые соединения интерферона

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CONJUCHEM BIOTECHNOLOGIES INC. (CA)

Free format text: TRANSFERIDO DE: CONJUCHEM INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: COLABOR GROUP INC. (CA)

Free format text: NOME ALTERADO DE: CONJUCHEM BIOTECHNOLOGIES INC.

B25G Requested change of headquarter approved

Owner name: COLABOR GROUP INC. (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020120015823/RJ DE 27/02/2012.

B25A Requested transfer of rights approved

Owner name: 4523482 CANADA INC. (CA)

Free format text: TRANSFERIDO DE: COLABOR GROUP INC.

B25A Requested transfer of rights approved

Owner name: 4503996 CANADA INC. (CA)

Free format text: TRANSFERIDO POR INCORPORACAO DE: 4523482 CANADA INC.

B25D Requested change of name of applicant approved

Owner name: CONJUCHEM BIOTECHNOLOGIES INC. (CA)

Free format text: NOME ALTERADO DE: 4503996 CANADA INC.

B25A Requested transfer of rights approved

Owner name: CALIFORNIA CAPITAL EQUITY, LLC (US)

Free format text: TRANSFERIDO DE: CONJUCHEM BIOTECHNOLOGIES INC.

B25A Requested transfer of rights approved

Owner name: CONJUCHEM LLC (US)

Free format text: TRANSFERIDO DE: CALIFORNIA CAPITAL EQUITY, LLC

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2224 DE 20/08/2013.